ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Zenith Drugs Limited has issued a notice for its 26th Annual General Meeting scheduled for September 29, 2026, to transact various ordinary and special business.
Zenith Drugs Limited announced the notice for its 26th AGM and appointed a secretarial auditor and a scrutinizer for the meeting.
Zenith Drugs Limited's board approved the allotment of 16,09,050 convertible warrants to promoters on a preferential basis. The aggregate consideration for this issuance is Rs. 6.99 Crore.
Zenith Drugs Limited held an EGM on July 23, 2026. Members considered the issuance of up to 16,09,050 fully convertible warrants to promoters.
Zenith Drugs issued a corrigendum to its EGM notice scheduled for July 23, 2026. Updates include details on a Rs. 36.58 Crore term loan and shareholding changes.
Zenith Drugs Limited called an EGM on July 23, 2026. The meeting aims to approve issuing 16,09,050 convertible warrants to promoters.
Zenith Drugs approved a Rs. 7 Crore preferential issue of convertible warrants. The warrants are exercisable into equity shares within 18 months.
Zenith Drugs approved issuing 16,09,050 warrants to promoters for ₹6.99 Crore. The preferential issue is subject to shareholder and regulatory approval.
Zenith Drugs re-submitted its FY26 financial results to correct a Rs. 1.60 Crore tax provision misclassification. The correction is administrative and does not impact reported profits.
Zenith Drugs Limited secured a ₹4.11 Crore tender from KSMSCL for pharmaceutical supply. The order involves delivering 29,10,826 bottles of Montelukast and Levocetirizine Syrup.
Zenith Drugs established a new Mother Depot in Bengaluru, Karnataka. This expansion strengthens its Southern India distribution network and aims to improve operational efficiency and product availability.
Zenith Drugs Limited received a ₹0.75 Crore export order from the Mauritius Ministry of Health. The contract for pharmaceutical products strengthens the company's international business portfolio.
Zenith Drugs Ltd reported revenue from operations of ₹93 Cr (+41.8% YoY) and net profit of ₹1.6 Cr (+14.3% YoY) for H2 FY26.
Zenith Drugs Limited reported audited financial results for the year ended March 31, 2026. The board also appointed internal auditors for the upcoming fiscal year.
Zenith Drugs Limited secured its first export orders worth ₹2.50 Crore in Afghanistan for 17 products. This marks a significant milestone in its international expansion strategy.
Zenith Drugs Limited scheduled a board meeting for May 29, 2026, to approve audited annual financial results. The trading window remains closed until June 2, 2026.
Zenith Drugs Limited submitted its Structured Digital Database compliance certificate for the financial year 2026. This confirms adherence to SEBI insider trading monitoring regulations.
Zenith Drugs Limited launched a new Mother Depot in Lucknow, Uttar Pradesh. This expansion aims to strengthen distribution and improve healthcare product accessibility.
Zenith Drugs secured a ₹3.93 Crore supply order from Karnataka State Medical Supplies Corporation Limited. The contract involves delivering oral rehydration salts, strengthening revenue visibility.
Zenith Drugs Limited has secured a tender from Madhya Pradesh Public Health Services Corporation Limited valued at ₹0.46 Crore. The contract involves supplying 5,14,447 tubes of Mupirocin Ointment. This award reinforces the company's growing presence in the domestic pharmaceutical supply segment.
Promoters of Zenith Drugs Limited submitted an annual declaration for FY 2025-26 under SEBI Takeover Regulations. The filing confirms that the promoter group and persons acting in concert did not create any encumbrances or pledges on their shareholding during the year. This is a routine regulatory compliance disclosure.